|
|
Volumn 27, Issue 9, 2009, Pages 779-780
|
|
Human genome sciences trial data wow lupus community
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
A 623;
ABATACEPT;
AMG 557;
ATACICEPT;
AUTOANTIBODY;
BELIMUMAB;
BENLYSTA;
CNTO 136;
EPRATUZUMAB;
IMMUNOGLOBULIN;
IMMUNOMODULATING AGENT;
IMMUNOSUPPRESSIVE AGENT;
LUPUZOR;
MEDI 545;
MONOCLONAL ANTIBODY;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
OCRELIZUMAB;
PEPTIDE ANTIBODY;
PLACEBO;
RITUXIMAB;
RONTALIZUMAB;
SIFALIMUMAB;
STEROID;
UNCLASSIFIED DRUG;
B LYMPHOCYTE;
CELL MATURATION;
CLINICAL TRIAL;
DRUG INDUSTRY;
DRUG RESPONSE;
DRUG TARGETING;
ERYTHEMATOSUS;
HUMAN;
HUMAN GENOME;
LUPUS ERYTHEMATOSUS;
LUPUS ERYTHEMATOSUS NEPHRITIS;
LUPUS EYTHEMATOSUS;
LUPUS VULGARIS;
LYMPHOMA;
NOTE;
OFF LABEL DRUG USE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SJOEGREN SYNDROME;
SYSTEMIC LUPUS ERYTHEMATOSUS;
TREATMENT FAILURE;
ANTIBODIES, MONOCLONAL;
BIOTECHNOLOGY;
CLINICAL TRIALS AS TOPIC;
HUMANS;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
|
|
EID: 70249131176
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0909-779 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|
